6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
Study Details
Study Description
Brief Summary
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent or progressive anaplastic glioma or glioblastoma multiforme in patients who have failed previous treatments. The safety of these combination treatment will also be studied.
Objectives:
1.1 To determine the efficacy, as measured by 12 month progression-free survival, of TEMOZOLOMIDE or CCNU with 6-THIOGUANINE followed by CAPECITABINE and CELECOXIB in the treatment of patients with recurrent and/or progressive anaplastic gliomas or glioblastoma multiforme.
1.2 To determine the long-term toxicity of TEMOZOLOMIDE or CCNU with 6-THIOGUANINE followed by CAPECITABINE and CELECOXIB in recurrent anaplastic glioma or glioblastoma multiforme patients treated in this manner.
1.3 To determine the clinical relevance of genetic subtyping tumors as a predictor of response to this chemotherapy and long term survival
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Capecitabine is a drug that damages the DNA (deoxyribonucleic acid) of tumor cells and blocks the function of DNA and RNA (ribonucleic acid) of tumor cells. These actions help to kill the tumor cells.
Celecoxib is a drug that may help to prevent the development of some types of cancer by blocking a type of enzyme (COX-2) that is found in tumor cells.
Temozolomide and CCNU are the current standard treatment for malignant brain tumors. Both drugs work by damaging the DNA (deoxyribonucleic acid) of tumor cells to kill these tumor cells.
6-Thioguanine is a drug that helps to increase the effects of Temozolomide and CCNU on tumor cells.
Depending on the previous treatment you have received, you will be treated according to Arms 1, 2, or 3.
If you have not received temozolomide before, you will be treated on Arm 1. If you have received temozolomide before but only during radiation therapy and not as chemotherapy afterwards and the treatment was over 6 months ago, you will be treated with temozolomide according to Arm 1.
If you have not received lomustine or carmustine, you will be treated on Arm 2. If you have received Gliadel wafers at surgery greater than 6 months ago and have not been treated with lomustine or carmustine, you will be treated with CCNU according to Arm 2.
Arm 3 will include glioblastoma multiforme patients who may be treated with either temozolomide or lomustine according to the above guidelines and regimens described in Arms 1 and 2.
Arm 1:
Treatment will begin with 6-thioguanine taken by mouth 4 times a day (every 6 hours) for 3 days in a row (Days 1-3). This will be followed by temozolomide taken by mouth at bedtime for 5 days in a row (Days 4-8). After a rest period of 6 days, capecitabine and celecoxib will be taken by mouth twice a day (12 hours apart) for 14 days (Days 14-27). Each cycle of treatment on arm 1 will be 28 days.
Arm 2:
Treatment will begin with 6-thioguanine taken by mouth 4 times a day (every 6 hours) for 3 days in a row (Days 1-3). This will be followed by lomustine taken by mouth at bedtime for 1 day (Day 4). After a rest period of 1 week, capecitabine and celecoxib will be taken by mouth twice a day (12 hours apart) for 14 days (Days 11-24). Each cycle of treatment on arm 2 will take 42 days.
Blood tests (less than 2 teaspoons) will be repeated every 2 weeks and before each new cycle of treatment (a total of about 2 tablespoons). The neurological exam, anticonvulsant level blood tests and the stool test for blood, will be repeated before every cycle on Arms 2 and 3 (CCNU) and before every 2 cycles on Arms 1 and 3 (temozolomide). Kidney function will be evaluated from the blood tests before every other course. Patients taking anticoagulants (coumadin, warfarin) will have procedures to test the clotting ability of the blood before each cycle or more frequently if the doctor feels it is necessary.
Arm 3:
Glioblastoma Multiforme patients will be treated on Arm 3 which will include the drug regimen from either Arm 1 or Arm 2.
Treatment on all arms will continue for 1 year as long as the tumor does not grow and any side effects are tolerable. Treatment may continue beyond one year if your doctor feels it is needed. During the study, you may not receive any other investigational drug or have any other treatment for the cancer, including surgery.
This is an investigational study. All drugs used in this study are FDA approved and are commercially available. A total of 140 patients will take part in this study. All patients will be enrolled at M. D. Anderson.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: 1: Anaplastic Tumors Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course. |
Drug: Capecitabine
Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
Other Names:
Drug: Celecoxib (Celebrex)
Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
Other Names:
Drug: Temozolomide
Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
Other Names:
Drug: 6-Thioguanine
Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
Other Names:
|
| Active Comparator: 2: Anaplastic Tumors Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24. Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide. |
Drug: Capecitabine
Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
Other Names:
Drug: Celecoxib (Celebrex)
Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
Other Names:
Drug: Lomustine
Arms 2,3 = 100 mg/m^2 PO on Day 4.
Other Names:
Drug: 6-Thioguanine
Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
Other Names:
|
| Active Comparator: 3: Glioblastoma Multiforme Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle. Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide. |
Drug: Capecitabine
Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
Other Names:
Drug: Celecoxib (Celebrex)
Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
Other Names:
Drug: Temozolomide
Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
Other Names:
Drug: Lomustine
Arms 2,3 = 100 mg/m^2 PO on Day 4.
Other Names:
Drug: 6-Thioguanine
Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- 12 Month-progression-free Survival for Participants With Anaplastic Tumors [12 months]
Progression-free Survival (PFS) at 12 months measured as percentage of participants that are alive and progression-free at 12 months (anaplastic tumors). A combination of neurological examination and MRI brain scan used to define overall response or progression.
- 6 Month Progression-free Survival for Participants With Glioblastoma [6 months]
Progression-free Survival (PFS) at 6 months measured as percentage of participants that are alive and progression-free at 6 months (glioblastoma multiforme). A combination of neurological examination and MRI brain scan used to define overall response or progression.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of this hospital.
-
Patients with histologically proven supratentorial anaplastic oligodendrogliomas, anaplastic mixed oligoastrocytomas anaplastic astrocytomas or glioblastoma multiforme.
-
Patients must have unequivocal evidence for tumor recurrence or progression by MRI scan performed within 14 days prior to enrollment or documented recurrence by tumor resection. Patients must have received radiation therapy previously.
-
Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all the following conditions are met: a) Patients have recovered from the effects of surgery; b) Extent of residual disease (if present) has been documented by MRI performed no later than 72 hours after surgery or, if not possible, at least 4 weeks post-operative. Radiographic evidence of residual disease is not mandated for enrollment.
-
The baseline on-study MRI is performed within 14 days of enrollment and on a steroid dosage that has been stable. If the steroid dose is increased between the date of imaging and the initiation of chemotherapy, a new baseline MRI is required on stable steroids for 7 days.
-
Patients must be equal to or greater than 12 years old.
-
Patients must have a Karnofsky performance status of equal to or greater than 60 (Karnofsky Performance Scale; Appendix D).
-
Patients must have recovered from the toxic effects of prior therapy: 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count). Any questions related to the definition of non-cytotoxic agents should be directed to the Study Chair.
-
Patients must have adequate bone marrow function (ANC equal or greater than 1,500/mm3 and platelet count of equal or greater than 100,000/mm3), adequate liver function (SGPT and alkaline phosphatase <2 times normal, bilirubin <1.5 mg%), and adequate renal function (BUN and creatinine <1.5 times institutional normal) prior to starting therapy.
Exclusion Criteria:
-
Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years (1 year for localized prostate carcinoma treated by prostatectomy or irradiation) are ineligible.
-
Patients of childbearing potential must not be pregnant or become pregnant.
-
Patients must not have: a) active infection; b) disease that will obscure toxicity or dangerously alter drug metabolism; c) serious intercurrent medical illness; d) acute or chronic pulmonary disease, pulmonary embolus, hypertension, diabetes, metabolic syndrome, stroke, heart disease,myocardial infarction, angina, coronary angioplasty, congestive heart failure, or coronary bypass surgery; e) allergies to sulfa drugs; f) severe psychiatric illness; g) uncontrolled hypertension (i.e. ->135/>85 mm Hg) on three repeated measurements during the 6 weeks prior to enrollment on the study
-
Patients must not have (continued): h) family history of premature coronary disease (i.e. - onset < 55 years of age); i) uncontrolled hypercholesteremia [low-density lipoprotein cholesterol (LDL-C >130]. Hypercholesteremia must be controlled for at least 3 months prior to enrollment on study; j) history of systemic lupus erythematous, family history of protein S or C deficiencies, prior heparin-induced thrombocytopenia, Factor V Leiden deficiencies or high homocysteine levels; k) any indications for ASA deficiency
-
Patients must not have had prior treatment with Capecitabine, 5-FU or a combination of Temozolomide with CCNU (Lomustine) or BCNU (Carmustine). Patients who received only Temozolomide during radiation therapy and did not receive adjuvant chemotherapy with Temozolomide and/or those who received Gliadel (BCNU) wafers at surgery without adjuvant chemotherapy with BCNU or CCNU are eligible if 6 months has passed since the treatment(s).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UT MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
Investigators
- Principal Investigator: Charles Conrad, MD, UT MD Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2003-0600
Study Results
Participant Flow
| Recruitment Details | Recruitment period: September 23, 2003 to June 15, 2009. All patients recruited at UT MD Anderson Cancer Center. |
|---|---|
| Pre-assignment Detail | Of the 75 enrolled participants, one was excluded prior to assignment to groups. The Anaplastic Tumors Arms (Arm 1 and Arm 2) were combined for recruitment demographics and data collection. |
| Arm/Group Title | Anaplastic Tumors | Glioblastoma Multiforme |
|---|---|---|
| Arm/Group Description | 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 every 12 hours; and Celebrex 400 mg PO every 12 hours for 13 days for 28 day course. | 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle. Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide. |
| Period Title: Overall Study | ||
| STARTED | 31 | 43 |
| COMPLETED | 31 | 43 |
| NOT COMPLETED | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Anaplastic Tumors | Glioblastoma Multiforme | Total |
|---|---|---|---|
| Arm/Group Description | 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 every 12 hours; and Celebrex 400 mg PO every 12 hours for 13 days for 28 day course. | 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle. Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide. | Total of all reporting groups |
| Overall Participants | 31 | 43 | 74 |
| Age (Count of Participants) | |||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
29
93.5%
|
34
79.1%
|
63
85.1%
|
| >=65 years |
2
6.5%
|
9
20.9%
|
11
14.9%
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
14
45.2%
|
15
34.9%
|
29
39.2%
|
| Male |
17
54.8%
|
28
65.1%
|
45
60.8%
|
| Region of Enrollment (participants) [Number] | |||
| United States |
31
100%
|
43
100%
|
74
100%
|
Outcome Measures
| Title | 12 Month-progression-free Survival for Participants With Anaplastic Tumors |
|---|---|
| Description | Progression-free Survival (PFS) at 12 months measured as percentage of participants that are alive and progression-free at 12 months (anaplastic tumors). A combination of neurological examination and MRI brain scan used to define overall response or progression. |
| Time Frame | 12 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| Results from TMZ and CCNU treatment arms (Anaplastic Tumor-Glioma Arms 1 & 2) were combined in the final analysis because there was no statistically significant difference between them. |
| Arm/Group Title | Participants With Recurrent Anaplastic Glioma |
|---|---|
| Arm/Group Description | 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours; Arm 1 Temozolomide (TMZ) 150 mg/m^2 PO daily Days 4-8 OR Arm 2 Lomustine 100 mg/m^2 PO on Day 4; Arm 2 Participants if previously received Temozolomide but not Lomustine (CCNU) receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) receive Temozolomide. |
| Measure Participants | 31 |
| Number [percentage of participants] |
44
(5)
141.9%
|
| Title | 6 Month Progression-free Survival for Participants With Glioblastoma |
|---|---|
| Description | Progression-free Survival (PFS) at 6 months measured as percentage of participants that are alive and progression-free at 6 months (glioblastoma multiforme). A combination of neurological examination and MRI brain scan used to define overall response or progression. |
| Time Frame | 6 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Participants With Glioblastoma Multiforme |
|---|---|
| Arm/Group Description | 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle. Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide. |
| Measure Participants | 43 |
| Number [percentage of participants] |
14
45.2%
|
Adverse Events
| Time Frame | 6 years and 3 months | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Anaplastic Tumors | Glioblastoma Multiforme | ||
| Arm/Group Description | 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 every 12 hours; and Celebrex 400 mg PO every 12 hours for 13 days for 28 day course. | 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle. Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide. | ||
All Cause Mortality |
||||
| Anaplastic Tumors | Glioblastoma Multiforme | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Anaplastic Tumors | Glioblastoma Multiforme | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 8/31 (25.8%) | 16/43 (37.2%) | ||
| Blood and lymphatic system disorders | ||||
| Thrombocytopenia | 1/31 (3.2%) | 1 | 0/43 (0%) | 0 |
| Gastrointestinal disorders | ||||
| Vomiting | 1/31 (3.2%) | 1 | 3/43 (7%) | 3 |
| Diarrhea | 1/31 (3.2%) | 1 | 2/43 (4.7%) | 2 |
| Dysphagia | 0/31 (0%) | 0 | 1/43 (2.3%) | 1 |
| Nausea | 1/31 (3.2%) | 1 | 2/43 (4.7%) | 2 |
| General disorders | ||||
| Fatigue | 0/31 (0%) | 0 | 1/43 (2.3%) | 1 |
| Hemorrhage | 1/31 (3.2%) | 1 | 1/43 (2.3%) | 1 |
| Infections and infestations | ||||
| Pneumonitis | 1/31 (3.2%) | 1 | 0/43 (0%) | 0 |
| Metabolism and nutrition disorders | ||||
| Hyponatremia | 0/31 (0%) | 0 | 1/43 (2.3%) | 1 |
| Musculoskeletal and connective tissue disorders | ||||
| Muscle Weakness | 1/31 (3.2%) | 1 | 2/43 (4.7%) | 3 |
| Pain-Back | 1/31 (3.2%) | 1 | 1/43 (2.3%) | 1 |
| Nervous system disorders | ||||
| Increased intracranial pressure | 0/31 (0%) | 0 | 1/43 (2.3%) | 1 |
| Seizure | 1/31 (3.2%) | 1 | 1/43 (2.3%) | 1 |
| Mental Status | 0/31 (0%) | 0 | 1/43 (2.3%) | 1 |
| Hydrocephalus | 0/31 (0%) | 0 | 1/43 (2.3%) | 1 |
| Dizziness | 0/31 (0%) | 0 | 1/43 (2.3%) | 1 |
| Confusion | 1/31 (3.2%) | 1 | 1/43 (2.3%) | 1 |
| Vascular disorders | ||||
| Thrombosis/Embolism | 1/31 (3.2%) | 1 | 5/43 (11.6%) | 5 |
Other (Not Including Serious) Adverse Events |
||||
| Anaplastic Tumors | Glioblastoma Multiforme | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 31/31 (100%) | 43/43 (100%) | ||
| Blood and lymphatic system disorders | ||||
| ANEMIA | 6/31 (19.4%) | 16 | 3/43 (7%) | 4 |
| HEMOGLOBIN | 24/31 (77.4%) | 60 | 33/43 (76.7%) | 88 |
| LEUKOCYTES | 21/31 (67.7%) | 113 | 33/43 (76.7%) | 124 |
| LEUKOPENIA | 4/31 (12.9%) | 16 | 0/43 (0%) | 0 |
| LYMPHOPENIA | 21/31 (67.7%) | 160 | 33/43 (76.7%) | 147 |
| NEUTROPHILS (ANC/AGC) | 15/31 (48.4%) | 70 | 28/43 (65.1%) | 72 |
| PLATELETS | 23/31 (74.2%) | 108 | 31/43 (72.1%) | 96 |
| Cardiac disorders | ||||
| HYPERTENSION | 4/31 (12.9%) | 5 | 1/43 (2.3%) | 1 |
| Eye disorders | ||||
| BLURRED VISION | 7/31 (22.6%) | 7 | 9/43 (20.9%) | 13 |
| Gastrointestinal disorders | ||||
| ANOREXIA | 3/31 (9.7%) | 4 | 5/43 (11.6%) | 5 |
| CONSTIPATION | 15/31 (48.4%) | 32 | 15/43 (34.9%) | 18 |
| DIARRHEA | 8/31 (25.8%) | 14 | 14/43 (32.6%) | 18 |
| NAUSEA | 16/31 (51.6%) | 28 | 16/43 (37.2%) | 26 |
| VOMITING | 11/31 (35.5%) | 14 | 15/43 (34.9%) | 19 |
| General disorders | ||||
| FATIGUE | 24/31 (77.4%) | 37 | 30/43 (69.8%) | 48 |
| Immune system disorders | ||||
| ALLERGIC RHINITIS | 4/31 (12.9%) | 4 | 6/43 (14%) | 6 |
| Metabolism and nutrition disorders | ||||
| ALKALINE PHOSPHATASE | 5/31 (16.1%) | 6 | 7/43 (16.3%) | 9 |
| ALT SGPT | 10/31 (32.3%) | 13 | 14/43 (32.6%) | 18 |
| AST SGOT | 8/31 (25.8%) | 9 | 10/43 (23.3%) | 13 |
| BICARBONATE SERUM-LOW | 3/31 (9.7%) | 5 | 4/43 (9.3%) | 12 |
| BILIRUBIN | 2/31 (6.5%) | 8 | 4/43 (9.3%) | 10 |
| CREATININE | 3/31 (9.7%) | 5 | 1/43 (2.3%) | 1 |
| HYPERGLYCEMIA | 14/31 (45.2%) | 33 | 43/43 (100%) | 47 |
| HYPOALBUMINEMIA | 7/31 (22.6%) | 11 | 13/43 (30.2%) | 21 |
| HYPOCALCEMIA | 4/31 (12.9%) | 4 | 10/43 (23.3%) | 18 |
| HYPONATREMIA | 3/31 (9.7%) | 9 | 9/43 (20.9%) | 10 |
| HYPOPHOSPHATEMIA | 6/31 (19.4%) | 10 | 8/43 (18.6%) | 20 |
| Musculoskeletal and connective tissue disorders | ||||
| GAIT/WALKING | 12/31 (38.7%) | 19 | 13/43 (30.2%) | 18 |
| MUSCLE WEAKNESS | 10/31 (32.3%) | 20 | 26/43 (60.5%) | 45 |
| Nervous system disorders | ||||
| COGNITIVE DISTURBANCE | 5/31 (16.1%) | 6 | 5/43 (11.6%) | 5 |
| CONFUSION | 5/31 (16.1%) | 6 | 8/43 (18.6%) | 9 |
| MEMORY IMPAIRMENT | 11/31 (35.5%) | 14 | 18/43 (41.9%) | 20 |
| PYRAMIDAL TRACT DYSFUNCTION | 9/31 (29%) | 11 | 7/43 (16.3%) | 7 |
| SEIZURE | 10/31 (32.3%) | 14 | 17/43 (39.5%) | 29 |
| Psychiatric disorders | ||||
| INSOMNIA | 9/31 (29%) | 9 | 12/43 (27.9%) | 13 |
| Respiratory, thoracic and mediastinal disorders | ||||
| COUGH | 5/31 (16.1%) | 6 | 9/43 (20.9%) | 9 |
| Skin and subcutaneous tissue disorders | ||||
| ALOPECIA | 5/31 (16.1%) | 5 | 7/43 (16.3%) | 8 |
| BRUISING | 6/31 (19.4%) | 6 | 6/43 (14%) | 6 |
| RASH/DESQUAMATION | 4/31 (12.9%) | 4 | 6/43 (14%) | 7 |
| Vascular disorders | ||||
| THROMBOSIS/THROMBUS/EMBOLISM | 4/31 (12.9%) | 5 | 3/43 (7%) | 4 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Charles A. Conrad, MD / Professor |
|---|---|
| Organization | UT MD Anderson Cancer Center |
| Phone | 713-745-1896 |
| skang@mdanderson.org |
- 2003-0600